tipifarnib has been researched along with Cancer of Pancreas in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, RD; Li, H; Liao, J; Sun, L; Tong, X; Xu, D; Yang, GY | 1 |
| Chen, J; Goodin, S; Li, DL; Ma, YR; Ma, YY; Ren, X; Wang, X; Xu, XT; Zhang, K; Zhao, DG; Zheng, X; Zhou, RP | 1 |
| Conney, AH; Cui, XX; Ding, N; Du, Z; Gao, Z; Hu, C; Huang, H; Lin, Y; Rabson, AB; Shih, WJ; Wei, X; Zheng, X | 1 |
| Bouche, O; Bugat, R; De Porre, P; Eckhardt, SG; Maurel, J; Michiels, B; Smith, D; Steward, WP; van de Velde, H | 1 |
| Heinemann, V | 1 |
| Abbruzzese, JL; Alpaugh, RK; Beard, M; Cohen, SJ; Ho, L; Hudes, GR; Lewis, NL; McLaughlin, S; Meropol, NJ; Perez-Ruixo, JJ; Ranganathan, S; Rogatko, A; Thistle, AM; Verhaeghe, T; Wang, H; Weiner, LM; Wright, JJ | 1 |
| Humblet, Y; Karasek, P; Ma, Y; Neumann, H; Oettle, H; Perez Ruixo, J; Post, S; Safran, H; Schoffski, P; Szawlowski, A; Van Cutsem, E; van de Velde, H; Verslype, C; Vervenne, WL; Von Hoff, D | 1 |
| Choudary, A; Freeman, JW; Venkatasubbarao, K | 1 |
| Abbruzzese, JL; Giguere, JK; Iqbal, S; Macdonald, JS; McCoy, S; Wade, JL; Whitehead, RP | 1 |
1 review(s) available for tipifarnib and Cancer of Pancreas
| Article | Year |
|---|---|
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
4 trial(s) available for tipifarnib and Cancer of Pancreas
| Article | Year |
|---|---|
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Deoxycytidine; Double-Blind Method; Europe; Female; Gemcitabine; Humans; Incidence; Male; Middle Aged; Outcome Assessment, Health Care; Pain; Pain Measurement; Pancreatic Neoplasms; Patient Satisfaction; Placebo Effect; Quinolones; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Treatment Outcome; United States | 2009 |
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents; Carrier Proteins; Disease Progression; Farnesyltranstransferase; Female; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinolones; Treatment Outcome | 2003 |
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Neutropenia; Pancreatic Neoplasms; Placebos; Prognosis; Quinolones | 2004 |
A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: a Southwest oncology group (SWOG 9924) study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Farnesyltranstransferase; Fatigue; Female; Humans; Male; Middle Aged; Nausea; Pancreatic Neoplasms; Proto-Oncogene Mas; Quinolones; Survival Rate; Treatment Outcome | 2005 |
4 other study(ies) available for tipifarnib and Cancer of Pancreas
| Article | Year |
|---|---|
Inhibition of mutant Kras and p53-driven pancreatic carcinogenesis by atorvastatin: Mainly via targeting of the farnesylated DNAJA1 in chaperoning mutant p53.
Topics: Animals; Atorvastatin; Carcinogenesis; Cell Line, Tumor; Disease Models, Animal; Farnesyltranstransferase; Gene Expression Regulation, Neoplastic; HSP40 Heat-Shock Proteins; Humans; Mice; Molecular Chaperones; Mutant Proteins; Pancreas; Pancreatic Neoplasms; Prenylation; Proto-Oncogene Proteins p21(ras); Quinolones; Tumor Suppressor Protein p53 | 2019 |
Effects of atorvastatin in combination with celecoxib and tipifarnib on proliferation and apoptosis in pancreatic cancer sphere-forming cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Neoplastic Stem Cells; Pancreatic Neoplasms; Quinolones; Signal Transduction; Spheroids, Cellular | 2021 |
A triple combination of atorvastatin, celecoxib and tipifarnib strongly inhibits pancreatic cancer cells and xenograft pancreatic tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Celecoxib; Cell Line, Tumor; Cell Proliferation; Female; Heptanoic Acids; Humans; Injections, Intraperitoneal; Mice; Mice, SCID; Neoplasms, Experimental; Pancreatic Neoplasms; Pyrazoles; Pyrroles; Quinolones; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Farnesyl transferase inhibitor (R115777)-induced inhibition of STAT3(Tyr705) phosphorylation in human pancreatic cancer cell lines require extracellular signal-regulated kinases.
Topics: Adenocarcinoma; Alkyl and Aryl Transferases; Cell Cycle Proteins; Cell Growth Processes; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Interleukin-6; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-myc; Quinolones; Serine; STAT3 Transcription Factor; Trans-Activators; Tyrosine; Up-Regulation | 2005 |